Glenmark Pharmaceuticals U.S. > News

News

Press Releases

Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.

Glenmark Pharmaceuticals receives ANDA approval for Pimecrolimus Cream, 1%

August 30, 2019

Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)

August 26, 2019

Glenmark Pharmaceuticals receives ANDA approval for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg

July 9, 2019

Glenmark Pharmaceuticals receives ANDA approval for Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg

June 28, 2019

FDA Issues Complete Response Letter for Ryaltris™ (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg])

June 24, 2019

News

Search Result :-

Is an investigational new drug that has not been approved for commercial distribution in the United States.

August 30, 2019
Glenmark Pharmaceuticals receives ANDA approval for Pimecrolimus Cream, 1%

August 26, 2019
Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)

July 9, 2019
Glenmark Pharmaceuticals receives ANDA approval for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg

June 28, 2019
Glenmark Pharmaceuticals receives ANDA approval for Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg

June 24, 2019
FDA Issues Complete Response Letter for Ryaltris™ (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg])

US Media Contact

For media inquiries only, please contact Corporate Communications.
uscomms@glenmarkpharma.com

Investor Relations

For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.

POTASSIUM CHLORIDE EXTENDED RELEASE CAPSULES 750mg RECALL REIMBURSEMENT POLICY

Over-the-counter (OTC)

ACCESSIBLE PRODUCTS

Who We Are

Injectables

OUR GROWING LINE